

Chul Ha, M.D.
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Chul Ha, M.D.
Chul S. Ha, MD, is professor and chair emeritus of the Department of Radiation Oncology at the Mays Cancer Center, home to UT Health San Antonio MD Anderson. He is a nationally recognized expert in radiation oncology, especially for hematological malignancies such as lymphoma, myeloma and leukemia. He has a special expertise in unique treatment procedures such as total body irradiation in preparation for bone marrow transplant, total skin electron beam radiation therapy for certain skin malignancies and radioimmunotherapy for lymphomas. His current research interest includes the development of drugs that reduce the side effects of DNA damaging agents such as radiation and chemotherapy. He graduated summa cum laude from Rice University with a bachelor’s degree in biochemistry. He obtained his MD from Harvard Medical School and completed residency training at Harvard Joint Center for Radiation Therapy. He spent 14 years at the University of Texas M.D. Anderson Cancer Center before joining the faculty at University of Texas Health Science Center San Antonio.
Gender
- Male
Languages Spoken
- English
- Korean
Chul Ha | Radiation Oncology
Trust should be at the core of any personal relationship including physician and patient.
-
Credentials
Credentials
Positions
- Professor, University of Texas Health Science Center San Antonio
Certifications
- American Board of Radiology/Radiation Oncology
Education
- Medical School: Harvard Medical School, Boston, MA
- Internship: Harvard Medical School, Boston, MA
- Residency: Harvard Medical School, Boston, MA
-
Locations & Contact
Locations & Contact
Dr Ha was very courteous, understanding, very friendly and explained everything and answered my questions very thoroughly, and in a way I could understand. He was patient & showed compassion. His staff was also very friendly, helpful, & understanding.
Patient
-
Research & Publications
Research & Publications
Low-dose arsenic induces chemotherapy protection via p53/NF-kappaB-mediated metabolic regulation
Ganapathy, S., Xiao, S., Seo, S. J., Lall, R., Yang, M., Xu, T., Su, H., Shadfan, M., Ha, C. S. & Yuan, Z. M.
Oncogene doi: 10.1038/onc.2013.81(2013). PMID: 23524579
p53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan
Su, H., Ganapathy, S., Li, X., Yuan, Z. M. & Ha, C. S.
Int. J. Radiat. Oncol. Biol. Phys. 1;92(5):1116-22 (2015). PMID: 26025778; PMCID: PMC4509863
Tolerance of Phellodendron amurense Bark Extract (Nexrutine(R)) in Patients with Human Prostate Cancer
Swanson, G. P., Jones, W. E.,3rd, Ha, C. S., Jenkins, C. A., Kumar, A. P. & Basler, J.
Phytother. Res. 29(1):40-2 (2014). PMID: 25205619; PMCID: PMC4507270
-
Clinical Trials
Clinical Trials
Type of Cancer
Breast
ClinicalTrials.gov Identifier
NCT02750826
Principal Investigator
Chul Ha M.D.
Alliance A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study…
Type of Cancer
Breast
ClinicalTrials.gov Identifier
NCT03488693
Principal Investigator
Chul Ha M.D.
CCTG MA.39: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (CTMS# 18-0110)
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
ClinicalTrials.gov Identifier
NCT01872975
Principal Investigator
Chul Ha M.D.
NSABP-B-51/RTOG 1304 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Patholog
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer